Immunic, Inc. (IMUX) Q3 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates financial challenges with ongoing net losses and increased expenses, despite having cash to fund operations into Q3 2025. There are competitive and supply chain risks, and a lack of shareholder return plans. The Q&A reveals management's unclear responses and inability to provide guidance, raising uncertainty. While there is interest in partnerships, no specific details were provided. Overall, these factors suggest a negative sentiment, likely leading to a stock price decline in the range of -2% to -8% over the next two weeks.
Key Financial Performance
Cash and Cash Equivalents $59.1 million, expected to fund operations into Q3 2025.
R&D Expenses (Q3 2024) $21.4 million, up from $19.8 million (8.1% increase) year-over-year, driven by increased external development costs for clinical trials, partially offset by the deprioritization of the izumerogant program.
R&D Expenses (Nine Months 2024) $58.4 million, down from $63.9 million (8.6% decrease) year-over-year, primarily due to the deprioritization of the izumerogant program and completion of the Phase 1 trial of IMU-856, partially offset by increased costs for vidofludimus calcium and personnel expenses.
G&A Expenses (Q3 2024) $4.4 million, up from $3.8 million (15.8% increase) year-over-year, primarily due to increased personnel expenses.
G&A Expenses (Nine Months 2024) $14 million, up from $11.9 million (17.6% increase) year-over-year, mainly due to personnel, legal, and consultancy expenses.
Interest Income (Q3 2024) $0.8 million, unchanged year-over-year.
Interest Income (Nine Months 2024) $3 million, up from $2.5 million (20% increase) year-over-year, due to higher interest rates.
Change in Fair Value of Tranche Rights (Nine Months 2024) $4.8 million, a non-cash charge related to future tranches of a private placement.
Other Income (Q3 2024) $600,000, up from $35,000 year-over-year, primarily due to R&D tax incentives in Australia.
Other Income (Nine Months 2024) Negative $1.1 million, down from $1.3 million year-over-year, due to expenses related to tranche rights and decreased R&D tax incentives, partially offset by foreign exchange gains.
Net Loss (Q3 2024) $24.4 million or $0.24 per share, compared to a net loss of $22.8 million or $0.51 per share year-over-year.
Net Loss (Nine Months 2024) $75.3 million or $0.75 per share, compared to a net loss of $72 million or $1.63 per share year-over-year.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Vidofludimus Calcium: Vidofludimus calcium is positioned as a potential first-in-class oral treatment for multiple sclerosis (MS), with a dual mode of action that combines neuroprotective effects and anti-inflammatory properties.
IMU-856: IMU-856 is being prepared for Phase 2 clinical testing, targeting gastrointestinal disorders with a unique mechanism that promotes gut wall healing.
Market Opportunity for Vidofludimus Calcium: The potential peak sales for vidofludimus calcium are estimated to range from USD 2 billion to USD 6 billion, addressing a significant unmet need in the MS market.
Progressive MS Market: There are approximately 175,000 patients diagnosed with non-relapsing secondary progressive MS across major markets, representing a significant opportunity for vidofludimus calcium.
Strengthened Management Team: Jason Tardio was appointed as President and COO, enhancing the company's capabilities for the commercialization of vidofludimus calcium.
Board of Directors Expansion: Simona Skerjanec was appointed to the Board, bringing extensive experience in drug development and commercialization.
Partnership Discussions: Immunic is actively pursuing partnership discussions with global pharmaceutical companies to leverage the potential of vidofludimus calcium.
Clinical Trial Progress: The company is advancing its Phase 3 ENSURE trials and expects to report topline data from the Phase 2 CALLIPER trial in April 2025.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: Immunic's forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those discussed, highlighting potential regulatory challenges.
Competitive Pressures: The company faces significant competition in the multiple sclerosis market, particularly with the recent failures of BTK inhibitors, which may influence partnership discussions and market dynamics.
Clinical Development Risks: The success of ongoing clinical trials (ENSURE and CALLIPER) is critical; any unfavorable outcomes could impact the company's future prospects and market position.
Financial Risks: Immunic reported a net loss of approximately $24.4 million for Q3 2024, indicating financial strain that could affect operational capabilities and funding for ongoing projects.
Supply Chain Challenges: Increased external development costs related to clinical trials may indicate potential supply chain challenges affecting the timely execution of research and development activities.
Market Acceptance Risks: The potential for vidofludimus calcium to transform the MS market is contingent on its acceptance by healthcare providers and patients, which is uncertain.
Funding Risks: The company is exploring options for non-dilutive cash raises, indicating a need for additional funding to support ongoing and future projects.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Strengthening Management Team: In July, Jason Tardio was appointed as President and COO, focusing on the commercialization of vidofludimus calcium.
Board of Directors Enhancement: Simona Skerjanec was appointed to the Board, bringing extensive experience in drug development and commercialization.
Clinical Trials: Ongoing Phase 3 ENSURE Trials in relapsing MS and Phase 2 CALLIPER trial in progressive MS.
Partnership Discussions: Pursuing potential partnerships for vidofludimus calcium and other drug candidates.
Post COVID Syndrome Trial: Initiated RAPID_REVIVE trial to evaluate vidofludimus calcium's effects on fatigue in Post COVID syndrome.
ECTRIMS Congress Participation: Presented data on vidofludimus calcium at the 40th Congress of ECTRIMS.
IMU-856 Program Advancement: Advancing IMU-856 for gastrointestinal disorders, preparing for Phase 2 clinical testing.
Topline Data Expectations: Topline data from the Phase 2 CALLIPER trial is expected in April 2025.
Financial Position: Ended Q3 2024 with $59.1 million in cash, expected to fund operations into Q3 2025.
Peak Sales Projections: Vidofludimus calcium has potential peak sales ranging from $2 billion to $6 billion.
Phase 3 ENSURE Trials Completion: First ENSURE trial completion expected in Q2 2026, second in H2 2026.
Regulatory Approval Path: Potential for accelerated approval in PMS depending on CALLIPER trial results.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Shareholder Return Plan: Immunic has not announced any specific shareholder return plan, including share buyback or dividend programs, during this earnings call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What level of detail should we expect a topline readout across these populations for both your primary as well as your secondary endpoints presented, possibly CDW, NfL, and or GFAB?
A:We plan to really come out with detailed data on the general and the subforms, tested during the study, including clinical endpoint, confirmed disability worsening, the biomarker NfL, GFAB, and brain atrophy data.
Q:When might we expect the data from the Post COVID investigator-led trial?
A:We can’t give any guidance on the speed of recruitment as it is an investigator-sponsored trial, but we are excited about the specific analysis.
Q:Are you earmarking or making note of any type of sub-analysis going on in ENSURE or CALLIPER for these Post COVID syndrome patients?
A:It’s not predefined in the study, but we will see if that shows up in the general safety monitoring of the study.
Q:Can you comment on what do you see on a blinded basis for CALLIPER, in regards to safety and efficacy?
A:We see blinded data but can’t conclude anything from that.
Q:What hazard ratio for disability worsening will you be looking for in CALLIPER to feel good about vidofludimus’ potential in PMS?
A:There is no predefined bar, but a 20% benefit would be a big win for the molecule.
Q:Pending positive data, in CALLIPER, is there any opportunity for an accelerated registrational path in PMS?
A:That’s definitely an opportunity, but it depends on the data and the distribution of the data.
Q:Can you talk a little bit about the unmet need in PMS and specifically also the subgroups of PMS as well?
A:There is a huge unmet need in the progressive side of this disease, specifically, and the non-relapsing secondary progressive MS, phenotype or subtype.
Q:Can you share more details on the calculation of the peak sales mentioned, regarding market share?
A:We’ve done a lot of work to understand both the bottoms up and the top down of forecast and opportunity for this respective medicine.
Q:Is Immunic in any negotiations to partner with big pharmaceutical at this moment?
A:There is significant interest in vidofludimus calcium, and we are talking to just about every single one of them.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer regarding the speed of recruitment for the Post COVID trial, stating they cannot provide guidance as it is investigator-sponsored. Additionally, they did not provide specific details on the blinded data for CALLIPER, stating they cannot conclude anything from that.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Barr virus
COVID syndrome
Chief Officer
Congress
Epstein Barr
Nurr
Phase CALLIPER
Phase trial
Post COVID
President Chief
Secondary Progressive
Tardio President
Zoom portal
addition
benefit
calcium profile
concern
disease therapy
drug candidate
efficacy
experience
fatigue patient
form disease
investigator trial
life
mechanism
medicine
meeting
number patient
patient form
population
sale
sclerosis vidofludimus
sub
subgroup
syndrome patient
topline
tranche
IMUX Transcript
Immunic, Inc. (IMUX) Q3 2024 Earnings Call Transcript
Unknown11-9
The earnings call summary indicates financial challenges with ongoing net losses and increased expenses, despite having cash to fund operations into Q3 2025. There are competitive and supply chain risks, and a lack of shareholder return plans. The Q&A reveals management's unclear responses and inability to provide guidance, raising uncertainty. While there is interest in partnerships, no specific details were provided. Overall, these factors suggest a negative sentiment, likely leading to a stock price decline in the range of -2% to -8% over the next two weeks.
Immunic, Inc. (IMUX) Q2 2024 Earnings Call Transcript
Neutral8-9
Immunic, Inc. (IMUX) Q1 2024 Earnings Call Transcript
Neutral5-8
Immunic, Inc. (IMUX) Q4 2023 Earnings Call Transcript
Positive2-22
The earnings call summary indicates a positive sentiment with improved net losses, increased other income, and the potential for accelerated regulatory pathways for key programs. The Q&A section reveals optimism from the MS community and potential partnerships, despite some uncertainties in timelines and study designs. These factors, combined with a 22.3% improvement in net loss year-over-year, suggest a positive stock price movement over the next two weeks.
IMUX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
